Literature DB >> 20533461

Target visualization by MRI using the avidin/biotin amplification route: synthesis and testing of a biotin-Gd-DOTA monoamide trimer.

Lorenzo Tei1, Alessandro Barge, Simonetta Geninatti Crich, Roberto Pagliarin, Viviana Negri, Daniela Ramella, Giancarlo Cravotto, Silvio Aime.   

Abstract

To design efficient targeting strategies in magnetic resonance (MR) molecular imaging applications, the formation of supramolecular adducts between (strept)avidin ((S)Av) and tribiotinylated Gd-DOTA-monoamide complexes (DOTA=1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid) was explored. Two compounds based on the trivalent core of tris(2-aminoethyl)amine each containing three biotin molecules and one (L1) or three (L2) DOTA-monoamide (DOTAMA) ligands were synthesized. In these tribiotinylated derivatives the biotins are spaced far enough apart to allow the formation of the supramolecular adduct with the protein and to host the chelating units in between the (S)Av layers. Size exclusion HPLC analyses indicated complete formation of very high molecular weight polymers (>2 MDa) with (S)Av in solution. A (1)H NMR spectroscopy relaxometric study on the obtained polymeric adducts showed a marked increase of the relaxivity at 35-40 MHz as a consequence of the lengthening of the tumbling time due to the formation of Gd-chelates/(S)Av polymers. The most efficient Gd(3)L2/(S)Av polymeric system was used for a test in cell cultures. The target is represented by a neural cell adhesion molecule (NCAM), which is overexpressed in Kaposi's sarcoma cells and tumor endothelial cells (TEC) and that is efficiently recognized by a biotinylated tetrameric peptide (C3d-Bio). In vitro experiments showed that only cells incubated with both C3d-Bio and Gd(3)L2/SAv polymer were hyperintense with respect to the control. Relaxation rates of cell pellets incubated with Gd(3)L2/SAv alone were not significantly different from the untreated cells demonstrating the absence of a specific binding.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20533461     DOI: 10.1002/chem.201000508

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  6 in total

1.  Monovalent streptavidin that senses oligonucleotides.

Authors:  Steven K Taylor; Jingxian Wang; Natasa Kostic; Milan N Stojanovic
Journal:  Angew Chem Int Ed Engl       Date:  2013-04-19       Impact factor: 15.336

2.  Cross-beta nanostructures based on dinaphthylalanine Gd-conjugates loaded with doxorubicin.

Authors:  Carlo Diaferia; Eliana Gianolio; Teresa Sibillano; Flavia Anna Mercurio; Marilisa Leone; Cinzia Giannini; Nicole Balasco; Luigi Vitagliano; Giancarlo Morelli; Antonella Accardo
Journal:  Sci Rep       Date:  2017-03-22       Impact factor: 4.379

3.  Imaging of Dysfunctional Elastogenesis in Atherosclerosis Using an Improved Gadolinium-Based Tetrameric MRI Probe Targeted to Tropoelastin.

Authors:  Federico Capuana; Alkystis Phinikaridou; Rachele Stefania; Sergio Padovan; Begoña Lavin; Sara Lacerda; Eyad Almouazen; Yves Chevalier; Laurence Heinrich-Balard; René M Botnar; Silvio Aime; Giuseppe Digilio
Journal:  J Med Chem       Date:  2021-10-18       Impact factor: 7.446

4.  An ultrasensitive chemiluminescence biosensor for carcinoembryonic antigen based on autocatalytic enlargement of immunogold nanoprobes.

Authors:  Minjia Hao; Zhanfang Ma
Journal:  Sensors (Basel)       Date:  2012-12-13       Impact factor: 3.576

5.  Bifunctional chelates optimized for molecular MRI.

Authors:  Erik C Wiener; Marie-Caline Abadjian; Raghvendra Sengar; Luce Vander Elst; Christoffel Van Niekerk; Douglas B Grotjahn; Po Yee Leung; Christie Schulte; Curtis E Moore; Arnold L Rheingold
Journal:  Inorg Chem       Date:  2014-06-16       Impact factor: 5.165

6.  Peptide-Based Soft Hydrogels Modified with Gadolinium Complexes as MRI Contrast Agents.

Authors:  Enrico Gallo; Carlo Diaferia; Enza Di Gregorio; Giancarlo Morelli; Eliana Gianolio; Antonella Accardo
Journal:  Pharmaceuticals (Basel)       Date:  2020-01-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.